Antifungal pharmaceutical composition and application thereof

By developing single-alkyl chain cationic antifungal compounds such as C18-dimethylsulfonium and C18-trimethylammonium, targeting fungal mitochondria, solving the problems of limited effects and toxicity of existing antifungal agents, and achieving the use of multiple fungal pathogens The efficient killing and low toxicity ensures food production security.

CN118948815APending Publication Date: 2024-11-15UNIV OF EXETER
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411071558.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-04-04
Filing Date
2020-03-18
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing antifungal agents have limited effects on crop pathogens, and there are toxicity problems and environmental pollution risks. The rapid development of market-leading chemicals has led to the rapid emergence of resistance, and new antifungal agents are needed to ensure food production security.

Method used

A monoalkyl chain cationic antifungal compound including C18-dimethylsulfonium and C18-trimethylammonium was developed to inhibit oxidative phosphorylation and induce programmed cell death by targeting the multi-site action mode of fungal mitochondria. , reduce environmental and human toxicity.

Benefits of technology

It has achieved efficient killing of various fungal pathogens, reduced the risk of toxicity to humans and the environment, has a multi-site action mode, reduced the possibility of resistance development, and significantly improved the effect of crop protection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948815A_ABST
    Figure CN118948815A_ABST
Patent Text Reader

Abstract

The invention relates to an antifungal pharmaceutical composition and application thereof. The present invention provides a pharmaceutical composition comprising an antifungal agent of formula R-S + (R ') 2 or R-N + (R') 3 wherein R is a C17-C32 linear or branched alkyl group and each R 'is independently methyl, ethyl, propyl, isopropyl or butyl, and a pharmaceutically acceptable carrier or excipient.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the Chinese national phase patent application with international application number PCT / GB2020 / 050691, international application date March 18, 2020, and invention name “Antifungal Composition”, which entered the Chinese national phase on September 29, 2021 and has application number 202080026490.6. Technical Field

[0002] The present invention relates to an antifungal composition comprising a monoalkyl chain cationic antifungal compound. The present invention also relates to the use of the monoalkyl chain cationic compound as an antifungal agent. Specifically, the present invention relates to an antifungal composition, method and use. Background Art

[0003] Fungi are one of the biggest biological challenges facing crop plant health and therefore food security. This threat is exacerbated by intensive agricultural activities such as monoculture, where large tracts of genetically uniform varieties provide an ideal environment for generating new antifungal strains. In fact, the emergence of fungicide resistance has outpaced the discovery of antifungal agents. There are only a small number of "new" antifungal agents in the "pipeline", but they are derivatives of commonly used chemicals, such as those that target specific complexes of ergosterol biosynthesis or mitochondrial respiratory chains. Obviously, there is an urgent need for new antifungal agents with new modes of action, low toxicity to mammals and environmentally friendly. In addition, there is an increasing need to discover new antifungal agents to better protect animals (including humans) from fungal diseases. This is done against the background of the emergence of antifungal resistance to currently used clinical drugs (azoles). It is also expected that azoles will be replaced by preservative treatments in wall paints and treated wood.

[0004] One potential target for new fungicides is fungal mitochondria. These organelles are involved in a wide range of cellular processes, but most importantly host oxidative phosphorylation enzymes that provide chemical energy to fuel the cell. Oxidative phosphorylation relies on electron transport through the mitochondrial respiratory chain complexes in the inner mitochondrial membrane (Hirst, 2013). Fungal mitochondria differ from mammalian mitochondria in the composition and function of respiratory enzymes, making them attractive targets for new fungicides. In fact, two of the three market-leading single-target fungicides, namely succinate dehydrogenase inhibitors (SDHI) and strobilurins, disrupt the fungal mitochondrial respiratory chain, targeting respiratory complexes II and III. Mitochondria also generate reactive oxygen species (mROS) at complexes I and III, which, if dysregulated, can damage proteins and lipids in the inner mitochondrial membrane and trigger apoptosis. There is increasing evidence that this programmed cell death pathway exists in fungi and targeting this pathway is a promising strategy for the development of new antifungals.

[0005] Electron transport through the respiratory chain triggers the transport of protons across the inner membrane of mitochondria. This makes the matrix negatively charged and, therefore, it becomes a target for lipophilic cations. These molecules, which combine a cationic head group with a lipophilic moiety, cross the cell membrane and accumulate in the inner membrane of mitochondria, exposing their cationic moieties to the matrix. This behavior allows the delivery of therapeutic drugs into mitochondria, but can also inhibit respiratory enzymes. While this effect on mitochondrial function challenges the use of lipophilic cations in medicine, it could be the key to using lipophilic cations as botanical fungicides / antifungals.

[0006] Lipophilic cations are widely used as "cationic surfactant" disinfectants or as supplements in cosmetic and pharmaceutical preparations. Cationic surfactants, specifically quaternary ammonium compounds, are recognized for their antimicrobial activity, but have recently received increasing attention due to their potential use in controlling human pathogenic fungi. The term cationic surfactant means that these compounds exert their biocidal activity on the surface of pathogens. In fact, due to their amphiphilic structure, these molecules are expected to insert into the plasma membrane, and all antifungal lipophilic n-alkyl chain cations known to date appear to kill fungal cells by changing the permeability or function of the plasma membrane or by interacting with the fungal cell wall. This includes the lipophilic monoalkyl chain cation (SACC) dodecylguanidine (hereinafter referred to as "C12-G+"), which is the active ingredient of the fungicide dodecylguanidine. Dodecylguanidine is a protective fungicide widely used to control fruit scab and foliar diseases in orchards. Although C12-G+ is believed to penetrate fungal cells, it also enters the cell and is reported to inhibit important metabolic enzymes. It is unclear whether intracellular activity is the primary mode of action of C12-G+ or is a result of cellular leakage due to increased cellular permeability.

[0007] While C12-G+ can be used as a fungicide, it has some toxicity issues. Specifically, due to its toxicity to Daphnia magna (water flea), C12-G+ could cause environmental issues if used as a fungicide on crops or soil, as it could potentially run off into water bodies such as lakes and rivers.

[0008] Furthermore, although C12-G+ can be used as a fungicide, its efficacy is limited when used against certain fungi. For example, when used to inhibit ZymoSeptoria tritici or Magnaporthe oryzae on wheat and rice, respectively, C12-G+, while nominally effective, was unable to completely inhibit the resulting ZymoSeptoria tritici leaf blight and Magnaporthe oryzae, even at nominally high concentrations (75 μl / ml–100 μl / ml C12-G+).

[0009] Therefore, there is a constant need for more effective treatments against crop pathogens to ensure our future food production. The rapid development of fungicide resistance in market-leading chemistries makes it imperative to find new fungicides. These fungicides should (i) be active against pathogens that damage crops, (ii) target an essential process at multiple sites to reduce resistance development, and (iii) have low toxicity to humans and the environment.

[0010] It would therefore be advantageous to provide additional cationic surfactant-based antifungal compounds that improve upon the efficacy of known cationic surfactant-based antifungal compounds such as C12-G+ against specific fungi or against a broad range of fungi. As used herein, the term "antifungal" refers to a broad spectrum of toxic effects against members of all fungal phyla and oomycetes.

[0011] It would also be advantageous to provide additional cationic surfactant based antifungal compounds having reduced environmental and / or human toxicity as well as paint protection and prevention of decay of felled wood products.

[0012] In addition, it would also be advantageous to provide more effective cationic surfactant-based antifungal compounds, compositions and treatments that target fungal metabolism at multiple sites in one or more metabolic pathways. Ideally, such fungicides would employ a novel multi-site mode of action that targets essential processes in pathogenic cells.

[0013] Furthermore, it would be advantageous to provide effective cationic surfactant-based biocidal compounds which are effective against human and / or animal pathogens, such as pathogenic fungi, and which are effective against plant pathogens.

[0014] It is therefore an object of embodiments of the present invention to overcome or mitigate at least one of the problems of the prior art, whether described herein or not. Summary of the invention

[0015] According to a first aspect of the present invention, a composition is provided, which comprises a compound of formula RS + (R')2 or RN + (R')3 antifungal compound (A)

[0016] wherein R is a C17-C32 straight or branched chain alkyl; and

[0017] Each R' is independently methyl, ethyl, propyl, isopropyl or butyl.

[0018] Compound (A) may comprise any suitable counter anion, such as bromide, chloride, iodide, hydroxide, sulfate, bisulfate, and phosphate.

[0019] The composition is preferably an antifungal composition, but may also be an antibacterial composition or an antiarchaeal composition, or any combination thereof (eg, an antifungal and antibacterial composition, or an antifungal, antibacterial and antiarchaeal composition).

[0020] The present invention also provides a pharmaceutical composition comprising compound (A) and a pharmaceutically acceptable carrier or excipient, use of compound (A) as an antifungal agent, and a method for destroying, controlling or inhibiting fungi by contacting compound (A) with fungi.

[0021] In a preferred embodiment, R is C18-C24, preferably straight chain alkyl, C18-C22, preferably straight chain alkyl or C18-C20, preferably straight chain alkyl. In a particularly preferred embodiment, R is C18 straight chain alkyl.

[0022] In some embodiments, at least one R' is methyl or ethyl, and in preferred embodiments, all R' are methyl.

[0023] Particularly useful as compound (A) in the compositions, uses and methods of the present invention are C18-dimethylsulfonium (octadecyldimethylsulfonium or "C18-DMS+") and C18-trimethylammonium (octadecyltrimethylammonium or "C18-TMA+") having the following corresponding formulas:

[0024]

[0025] For example, the composition may include a solution, suspension, emulsion, powder, paste, granules, gel, mousse or dust.

[0026] The composition may include a carrier. The carrier may include a solvent, which may be water or an aqueous solvent. Therefore, the composition may be an aqueous composition of compound (A) in water or an aqueous solvent. The aqueous solvent may include water and a co-solvent, which may be selected from, for example, methanol and ethanol.

[0027] The antifungal composition may comprise compound (A) at a concentration of at least 0.1 μg / ml, 0.2 μg / ml, 0.3 μg / ml, 0.4 μg / ml, 0.5 μg / ml, 0.75 μg / ml, 1 μg / ml, 1.5 μg / ml, 2 μg / ml, 2.5 μg / ml, 5 μg / ml, 7.5 μg / ml, 10 μg / ml, 15 μg / ml, 20 μg / ml, 30 μg / ml, 40 μg / ml, 50 μg / ml, 60 μg / ml, 70 μg / ml, 75 μg / ml, at least 100 μg / ml, at least 200 μg / ml, at least 250 μg / ml, at least 500 μg / ml or at least 1000 μg / ml of the composition.

[0028] In some embodiments, the composition comprises compound (A) at a concentration between 0.1-1000 μg / ml, such as between 0.1-250 μg / ml or between 0.1-200 μg / ml.

[0029] For some applications, such as applying the composition to crop plants (e.g., wheat, barley, oats, rice, sorghum, plantain, corn, potato, vegetables or fruit), horticultural plants and trees, the composition may contain compound (A) at a concentration between 10-1000 μg / ml, such as between 20-500 μg / ml, between 25-250 μg / ml or between 10-100 μg / ml.

[0030] In some embodiments, the composition may include an adjuvant. The adjuvant can enhance the efficacy of the antifungal compound (A). The mechanism of action of suitable adjuvants includes buffering water to the pH at which the particular antifungal compound is most active, conditioning water (for example, when hard water is used to solvate or dilute the antifungal compound, they may reduce the potential inhibitory effects of minerals such as calcium and magnesium), reducing the surface tension of water ("wetting agents"), thereby allowing the antifungal composition to have greater surface coverage when applied. Adjuvants may include solvents that make the surface (such as the leaf cuticle of the plant to which the composition is applied) more accessible to the antifungal compound; or they may include nutrients that can help the antifungal compound when applied to crops or other plants, such as to promote plant growth, or nutrients that make compound (A) more effective for actively growing plants. Other suitable adjuvants are defoamers, adjuvants that reduce drift during the spraying of antifungal compounds, and adjuvants that can reduce evaporation and volatility of antifungal compounds.

[0031] The adjuvant may be a compound selected from the group consisting of: a pH buffer; a water conditioner; a wetting agent; a leaf cuticle and / or cell membrane penetration aid; a plant growth promoter; an antifoaming agent; a spray drift reducer; and / or an evaporation reducer; or any combination thereof.

[0032] Adjuvants may be in the form of crop protection spray additives and / or surfactants. Adjuvants may increase the permeability of plant cuticles and / or cell membranes. Adjuvants may be nonionic spreading and penetration aids; and / or act to reduce the surface tension of the composition.

[0033] Adjuvants can enhance the fungicidal activity of the compound (A), for example by increasing the permeability of the cuticle and / or cell membranes. Adjuvants can enhance the fungicidal activity of the compound (A), for example by increasing the permeability of the plant cuticle and / or cell membranes.

[0034] For example, an adjuvant may be an additive to a crop protection spray, such as a surfactant; a nonionic spreading and penetration aid; and / or function to reduce the surface tension of the composition.

[0035] The adjuvant may include an activated adjuvant or a multi-purpose adjuvant.

[0036] Activated adjuvants are compounds that enhance the antifungal activity of a composition comprising compound (A) when added thereto. Activated adjuvants include, for example, surfactants, oil carriers such as phytobland oil (harmless to plants), crop oils, crop oil concentrates (COC), vegetable oils, methylated seed oils (MSO), petroleum and silicone derivatives, and nitrogen fertilizers.

[0037] Multi-purpose adjuvants (sometimes also called spray modifiers) can alter the physical or chemical properties of a composition to make it easier to apply, such as by increasing its adhesion to plant surfaces so that it is less likely to roll off, or by increasing its persistence in the environment.

[0038] One or more oils may be used as an adjuvant carrier or diluent for compound (A).

[0039] Salts may also be used as active adjuvants, such as to increase the absorption and action of the antifungal compound on a target surface, material or plant over time.

[0040] One or more surfactant adjuvants may be present in the composition to promote or enhance the emulsifying, dispersing, spreading, adhesive or wetting properties of the composition.

[0041] When the composition is applied to a material (such as a surface, plant leaves, etc.), the surfactant reduces the surface tension in the spray droplets of the composition, which helps the composition to spread and cover the target material with a thin film, thereby causing the composition to be absorbed into the material more effectively or more quickly. When sprayed on the stems or leaves of plants, the surfactant can also affect the absorption of the composition by changing the viscosity and crystal structure of the wax on the surface of the leaves and stems, making them more easily penetrated by the compound (A) of the composition.

[0042] The surfactant may be selected to enhance the antifungal properties of the composition by any one or more of the following: a) spreading the composition more evenly over the material to which it is applied; b) improving the retention (or 'stickiness') of the composition on the material; c) for plant or crop protection applications, increasing the penetration of the composition through the hairs, scales or other leaf surface structures of the plant; d) preventing crystallization of the composition; and / or e) slowing the drying of the composition.

[0043] Each surfactant may be selected from nonionic surfactants, ionic surfactants, amphoteric surfactants or zwitterionic surfactants, or any combination thereof.

[0044] Nonionic surfactants are generally biodegradable and compatible with many fertilizers and therefore may be preferred in the compositions of the present invention when used in crop or plant protection applications. Some nonionic surfactants are waxy solids and require the addition of cosolvents (such as alcohols or glycols) to dissolve into liquids. Glycol cosolvents are generally preferred over alcohols because the latter are flammable, evaporate quickly, and may increase the number of fine spray droplets (making the formulation likely to drift when sprayed).

[0045] The nonionic surfactant may comprise an organosilicon or silicone surfactant (including siloxanes and organosilicones). Organosilicon surfactants significantly reduce the surface tension of the composition, allowing the composition to form a thin layer on the surface of the leaves or stems of plants during use. Silicone surfactants can also reduce surface tension and allow the composition to penetrate the stomata of plant leaves. Silicone surfactants also provide a protective effect for the composition of the present invention by making the composition very difficult to wash off after application. Silicone surfactants can also affect the amount / rate of absorption of the antifungal compound (A) through the cuticle of the leaves.

[0046] In other embodiments, the nonionic surfactant may include a carbamide surfactant (also known as a urea surfactant). The carbamide surfactant may include, for example, dihydrogen sulfate monourea.

[0047] Suitable ionic surfactants include cationic surfactants and anionic surfactants. Suitable cationic surfactants include tallow amine ethoxylates. Suitable anionic surfactants include sulfates, carboxylates and phosphates attached to lipophilic hydrocarbons, including, for example, linear alkylbenzene sulfonates.

[0048] Amphoteric surfactants contain both positive and negative charges and generally function similarly to nonionic surfactants. Suitable amphoteric surfactants include, for example, lecithin (phosphatidylcholine) and amidopropylamine.

[0049] Multi-purpose adjuvants (sometimes referred to as spray modifiers) are capable of modifying the physical or chemical properties of the compositions of the invention, making the composition easier to apply, which can increase its adhesion to plant surfaces so that the composition has a reduced risk of being removed from the surface; or increase the persistence of the composition in the environment or treatment area where the composition is present.

[0050] Examples of different functional categories of multipurpose adjuvants suitable for use in the compositions and uses of the present invention include wetting agents, spreading agents, drift control agents, foaming agents, dyes, thickeners, deposition agents (stickers), water conditioners, wetting agents, pH buffers, defoamers, antifoaming agents and ultraviolet light absorbers. Some multipurpose adjuvants can function in more than one of the above functional categories. Some activated adjuvants are also multipurpose adjuvants.

[0051] Wetting agents or spreading agents reduce the surface tension in the composition and cause the composition to form a large, thin layer on the leaves and stems of the target plant. Since these agents are usually nonionic surfactants diluted with water, alcohols or glycols, they can also be used as activated adjuvants (surfactants). However, some wetting agents or spreading agents only affect the physical properties of the composition and do not affect the behavior of the composition after contact with the plant.

[0052] Drift control agents can be used to reduce spray drift of the composition, which is most often caused when fine (<150 μm diameter) spray droplets are carried away from the target area by air currents when the composition is sprayed onto plants. Drift control agents can alter the viscoelastic properties of the spray solution, producing a coarser spray with a larger average droplet size and weight, and minimizing the number of small droplets that are easily airborne. Suitable drift control agents may include large polymers such as polyacrylamides, polysaccharides, and certain types of gums.

[0053] Suitable deposition agents (stickers) include, for example, film-forming plant gels, emulsifiable resins, emulsifiable mineral oils, vegetable oils, waxes and water-soluble polymers. Deposition agents can be used to reduce the loss of the composition from the target plant due to volatilization of the composition from the target surface or beading and falling of the composition. Deposition agents are particularly suitable for the compositions of the present invention in the form of dry (wettable) powders and granular formulations.

[0054] Defoamers and antifoaming agents are capable of reducing, inhibiting or destroying the formation of foam in a container in which the composition of the present invention may be contained. Suitable defoamers include, for example, oils, polydimethylsiloxanes and other silicones, alcohols, stearates and glycols.

[0055] One or more adjuvants may include BREAK- S240, BREAK- SP 131, BREAK- SP 133, BREAK- S233, BREAK- OE 446, Aduro (RTM) and / or Transport Ultra (RTM). BREAK- S240 is a polyether trisiloxane that imparts super spreadability and greatly reduces surface tension. BREAK-THRU SP131 consists of polyglycerol fatty acid esters and polyethylene glycol, which are able to enhance the performance of antifungal compounds.

[0056] BREAK- SP 133 is based on polyglycerol esters and fatty acid esters. BREAK- S233 is a nonionic trisiloxane surfactant that increases the deposition of agricultural sprays and improves the penetration of insecticide actives into plant tissues. BREAK- OE 446 is a polyether polysiloxane.

[0057] Transport Ultra (RTM) contains a blend of nonionic surfactants, aminated ions, water conditioning agents and anti-foaming agents.

[0058] Aduro (RTM) contains dihydrogen sulfate monourea and alkylamine ethoxylate.

[0059] In some preferred embodiments, at least one adjuvant is selected from silicones, siloxanes, alkylamine ethoxylates or carboxamides. The adjuvants are particularly suitable for enhancing the effect of antifungal compounds, or otherwise increasing or accelerating the uptake of antifungal compounds by plants (particularly, vascular plants and mosses).

[0060] In some embodiments, the adjuvant may include: a nonionic surfactant; and / or an anti-foaming agent; and / or ammonium ions; and / or a water conditioning agent; and / or a polyether-polymethylsiloxane-copolymer; and / or a polyether polysiloxane; and / or polyglycerol fatty acid esters and polyethylene glycols; and / or polyglycerol esters and fatty acid esters; and / or a nonionic trisiloxane.

[0061] In a preferred embodiment, the composition comprises at least one surfactant, which may be a nonionic surfactant. In some embodiments, the composition comprises at least one silicone or siloxane, which may act as a surfactant and / or anti-foaming agent and / or wetting agent.

[0062] In addition to compound (A), the antifungal composition may also contain one or more additional antifungal agents. Additional antifungal agents may be selected from azoles; amino derivatives; strobilurins; specific anti-powderyngospore compounds; anilinopyrimidines; benzimidazoles and analogs; dicarboximides; polyhalogenated fungicides; systemic acquired resistance (SAR) inducers; phenylpyrroles; acylalanines; anti-downy mildew compounds; dithiocarbamates; arylamidines; phosphorous acid and its derivatives; fungicidal copper compounds; plant-based oils (vegetal preparations); chitosan; sulfur-based fungicides; fungicidal amides; and nitrogen heterocycles; or any combination thereof.

[0063] According to a second aspect of the present invention, there is provided a + (R')2 or RN + Use of biocidal compounds (A) of (R')3 as antifungal, antibacterial or antiarchaeal agents

[0064] wherein R is a C17-C32 straight or branched chain alkyl; and

[0065] Each R' is independently methyl, ethyl, propyl, isopropyl or butyl.

[0066] Compound (A) may be as described and defined above for the first aspect of the invention, and is preferably octadecyldimethylsulfonium or octadecyltrimethylammonium.Compound (A) may be present in the antifungal composition of the first aspect of the invention.

[0067] According to a third aspect of the present invention, there is provided a + (R')2 or RN + (R')3 biocidal compound (A)

[0068] wherein R is a C17-C32 straight or branched chain alkyl; and

[0069] Each R' is independently methyl, ethyl, propyl, isopropyl or butyl;

[0070] The biocidal compounds (A) are useful for treating diseases, preferably fungal diseases.

[0071] Compound (A) may be as described and defined above, and is preferably octadecyldimethylsulfonium or octadecyltrimethylammonium.Compound (A) may be present in the antifungal composition of the first aspect of the invention.

[0072] The disease may be a phytopathogenic disease. The phytopathogenic disease may be a fungal disease of a plant or its seeds, such as cereals (wheat, barley, rye, oats, rice, corn, sorghum, etc.), fruit trees (apple, pear, plum, peach, apricot, cherry, banana, grape, strawberry, raspberry, blackberry, etc.), citrus trees (orange, lemon, tangerine, grapefruit, etc.), legumes (soybean, pea, lentil, soybean, etc.), vegetables (spinach, lettuce, asparagus, cabbage, carrot, onion, tomato, potato, eggplant, pepper, etc.), Cucurbitaceae (pumpkin, zucchini, cucumber, melon, watermelon, etc.), oil-producing plants (sunflower, rapeseed, peanut, castor, coconut, etc.), tobacco, coffee, tea, cocoa, sugar beet, sugar cane, cotton, and / or horticultural plants.

[0073] Plant pathogenic fungi and oomycete species for which compound (A) can be used include Basidiomycetes, Ascomycetes, Deuteromycetes or Imperfectomycetes, Chytridiomycetes, Zygomycetes, Microsporidia and Oomycetes. These include, but are not limited to, Puccinia spp., Ustilago spp., Tilletia spp., Uromyces spp., Phakopsora spp., Rhizoctonia spp., Erysiphe spp., Sphaerotheca spp., Podosphaera spp., Uncinula spp., Helminthosporium spp., Rhynchosporium spp., Pyrenophora spp., Monilinia spp., Sclerotinia spp., Septoria spp. (Mycosphaerella spp.), Zymoseptoria spp.), Venturia spp., Botrytis spp., Alternaria spp., Fusarium spp., Cercospora spp., Cercosporella herpotrichoides, Colletotrichum spp., Pyricularia oryzae, Sclerotium spp., Phytophthora spp., Pythium spp., Plasmopara viticola, Peronospora spp., Pseudoperonospora cubensis, Bremia lactucae.

[0074] Specific fungal species infections against which compound (A) may be used include: Erysiphe graminis in cereals, Septoria tritici in cereals (especially wheat), Magnaporthe grisea in cereals (especially rice), Erysiphe cichoracearum and Sphaerotheca fuliginea in cucurbits, Podosphaera leucotricha in apples, Uncinulanecator in grapevines, Venturia inaequalis (black scab) in apples, Helminthosporium species in cereals, Septoria nodorum in wheat, Botrytis cinerea (grey mold) in strawberries and grapes, Cercospora arachidicola in peanuts, Pseudocercosporella in wheat and barley. herpotrichoides, Pyricularia oryzae in rice, Fusarium and Verticillium species in various plants, and Alternaria in fruits and vegetables.

[0075] Examples of plant fungal diseases against which compound (A) can be used include, but are not limited to, spot (particularly Septoria tritici leaf blight), rot, Fusarium wilt, stem rot, black root rot, Threonine root rot, blast (particularly rice blast), cotton rot, smut, soybean rust, corn rust, potato blight, mildew, root knot, anthracnose, damping-off, Rhizoctonia rot, bottom rot, spot, target spot, leaf blight, leaf spot, ring spot, black shank, stem blight, black knot, ergot, leaf blisters, scab, snow mold, sooty mold and verticillium wilt.

[0076] In some embodiments, the disease may be an animal pathogenic fungal disease, which in some embodiments may be independently selected from the diseases in the following table:

[0077]

[0078]

[0079] Therefore, compound (A) can be used to treat many common human and animal fungal infections, including candidiasis, tinea tinea and dermatophytosis.

[0080] According to a fourth aspect of the present invention, there is provided a method of treating a fungus with a formula RS + (R')2 or RN +Method for destroying, controlling or inhibiting fungi by contacting a compound (A) with (R')3

[0081] wherein R is a C17-C32 straight or branched chain alkyl; and

[0082] Each R' is independently methyl, ethyl, propyl, isopropyl or butyl.

[0083] Compound (A) may be as described and defined above, and is preferably octadecyldimethylsulfonium or octadecyltrimethylammonium.Compound (A) may be present in the antifungal composition of the first aspect of the invention.

[0084] The method may comprise contacting the fungus with an antifungal composition of the first aspect of the invention.

[0085] Controlling or inhibiting fungi may include controlling the growth and / or lifespan of the fungi.

[0086] The method may include destroying, controlling or inhibiting fungal infection of plants (including cut or growing plants or plant parts), seeds, animals (including humans, non-human mammals and other non-human animals), soil or ecosystems.

[0087] When compound (A) or a composition thereof is applied to the soil or ecosystem floor, the application rate may be from 0.02 kg to 3 kg or more of active ingredient per hectare, depending on the type of effect desired.

[0088] The plant may be a vascular plant and in some embodiments is selected from a crop plant or a tree. Compound (A) or a composition comprising compound (A) may be applied by spraying or sprinkling the plant with the active ingredient or treating the seeds of the plant with the active ingredient. They may be applied before or after the plant or seed is infected by one or more fungi.

[0089] In other embodiments, the method may include destroying, controlling or inhibiting fungi in building materials or construction materials. Building materials or construction materials may include wood (unfinished or treated), wall coverings, bricks, blocks, gypsum board, floor coverings or paint.

[0090] Suitable wall coverings include, for example, cladding, wallpaper, ceramic wall coverings (such as tiles), rubber, polymer coatings, paints, varnishes and lacquers. Floor coverings include, for example, carpets, linoleum, wooden boards or blocks, tiles, varnishes and paints. Compound (A) or a composition comprising compound (A) can be applied to a wall covering or floor covering by spraying or sprinkling the covering, or by impregnating the covering with compound (A) or a composition comprising compound (A).

[0091] Compositions such as solutions, emulsions, suspensions, powders, dusts, pastes and granules comprising compound (A) can be applied to building or construction materials by, for example, spraying, atomizing, sprinkling, spreading, dressing or watering.

[0092] According to a fifth aspect of the present invention, there is provided a building or construction material or composition comprising a compound of formula RS + (R')2 or RN + (R')3 compound (A)

[0093] wherein R is a C17-C32 straight or branched chain alkyl; and

[0094] Each R' is independently methyl or ethyl.

[0095] For example, compound (A) may be impregnated in a building or construction material or composition, or may comprise a coating thereon.The building or construction material may be selected from wood (unfinished or treated), wall covering, brick, plasterboard, floor covering or paint.

[0096] The building or construction material or composition may be a material or composition which has been treated (such as sprayed, coated or impregnated) by the method of the fourth aspect of the invention.

[0097] According to a sixth aspect of the present invention, there is provided a pharmaceutical composition comprising an antifungal compound (A) of the formula R-S+(R')2 or R-N+(R')3

[0098] wherein R is a C17-C32 straight or branched chain alkyl; and

[0099] Each R' is independently methyl, ethyl, propyl, isopropyl or butyl;

[0100] and pharmaceutically acceptable carriers or excipients.

[0101] Compound (A) may be as described and defined above for the first aspect of the invention, and in preferred embodiments is octadecyldimethylsulfonium ("C18-DMS+") or octadecyltrimethylammonium (C18-TPP+).

[0102] The pharmaceutical composition of the second aspect of the present invention can be used to treat humans or non-human animals, especially non-human mammals. Suitable non-human mammals include, for example, sheep, goats, cattle, pigs, dogs, cats and horses. Other animals may include, for example, chickens, geese, ducks, turkeys or other birds.

[0103] The pharmaceutically acceptable carrier or excipient may be a solvent, preferably an aqueous solvent. In some embodiments, the aqueous solvent may be water. In other embodiments, the aqueous solvent may comprise a mixture of water and a co-solvent. The co-solvent may be an alcohol and may be selected from methanol, ethanol and combinations thereof.

[0104] The pharmaceutical composition may be in a topically administrable form. Thus, the pharmaceutical composition may be a topically administrable pharmaceutical composition.

[0105] The term "topical application" relates to applying a substance to a body surface, such as the skin. In a preferred embodiment, topical application is to the skin (directly on the skin surface), also known as "dermal application".

[0106] The pharmaceutical composition can be provided in any form suitable for topical administration, including but not limited to ointments, gels, creams, lotions, foams, sprays, mousses, patches, powders, pastes, hydrogels, emulsions (including oil-in-water, water-in-oil, oil-in-water-in-oil, water-in-oil-in-water emulsions), or any combination thereof. In some preferred embodiments, the pharmaceutical composition is provided as a cream, ointment, lotion or gel, most preferably provided as a cream or ointment.

[0107] In some embodiments, the carrier or diluent may be an aqueous carrier or diluent, which itself may comprise water such as deionized water, or a mixture of water and another solvent. Suitable mixtures include, for example, water and polar protic solvents such as methanol, ethanol, propanol, isopropanol and butanol.

[0108] The carrier or diluent may alternatively comprise a hydrophobic carrier or diluent which may be selected from oils or fats, natural waxes, petroleum waxes, hydrocarbons or any suitable mixtures thereof. Alternatively, the carrier or diluent may comprise an organic solvent.

[0109] Suitable natural waxes include beeswax (including white or yellow beeswax), carnauba wax, wool wax, lanolin (such as purified lanolin or anhydrous lanolin), or any suitable combination thereof.

[0110] Suitable petroleum waxes include hard paraffins and microcrystalline waxes.

[0111] Suitable hydrocarbons include liquid paraffin, soft paraffin (including white or yellow soft paraffin), white petrolatum, yellow petrolatum, or any suitable combination thereof.

[0112] The pharmaceutical composition may comprise any other suitable carrier or diluent, such as those described in the British Pharmacopoeia, 2017 edition or the European Pharmacopoeia, 9th edition.

[0113] Suitable organic solvents include, but are not limited to, non-polar solvents, polar aprotic solvents, and polar protic solvents.

[0114] Suitable non-polar solvents include alkanes (such as hexane and pentane), cycloalkanes (such as cyclopentane and cyclohexane), benzene, toluene, chloroform, diethyl ether and dichloromethane.

[0115] Suitable polar aprotic solvents include tetrahydrofuran, ethyl acetate, acetone, dimethylformamide, acetonitrile, dimethyl sulfoxide and propylene carbonate.

[0116] Polar protic solvents include, but are not limited to, alcohols (such as methanol, ethanol, propanol, isopropanol, and butanol), formic acid, and acetic acid.

[0117] The use of an organic solvent as defined above is particularly useful for pharmaceutical compositions that are, for example, in the form of a spray. Sprays may be used to ensure that hard to reach areas of the skin are coated with the pharmaceutical composition, for example between the hooves or under skin folds.

[0118] In some embodiments, compound (A) may be encapsulated. In some embodiments, compound (A) may be incorporated into liposomes. For encapsulated compound (A) and liposome-entrapped compound (A), the pharmaceutical composition of the present invention may include an aqueous carrier, including water itself. Compound (A) may be microencapsulated. Suitable encapsulating agents for encapsulation or microencapsulation include, for example, yeast cells, exine shell materials (such as from pollen grains), etc.

[0119] The pharmaceutical composition of the present invention may also comprise one or more pharmaceutical excipients. Suitable pharmaceutical excipients include, but are not limited to, emulsifiers, surfactants, solvents, co-solvents, preservatives, stabilizers, buffers, solubilizers, dispersants, antioxidants, thickeners, softeners, lubricants, emollients, and one or more additional skin healing agents or conditioning agents.

[0120] The pharmaceutical composition of the present invention may also comprise one or more pharmaceutical excipients. Suitable pharmaceutical excipients include, but are not limited to, emulsifiers, surfactants, solvents, co-solvents, preservatives, stabilizers, buffers, solubilizers, dispersants, antioxidants, thickeners, softeners, lubricants, emollients, and one or more additional skin healing agents or conditioning agents.

[0121] Suitable preservatives include one or more selected from the list comprising: quaternary ammonium compounds, such as benzalkonium chloride (N-benzyl-N-(C8-C18-alkyl)-N,N-dimethylammonium chloride), benzozolium chloride, benzethonium chloride, cetrimide (hexadecyl-trimethylammonium bromide), closapazole, cetylpyridinium chloride, domiphene bromide, etc.; quaternary ammonium cyclodextrin compounds (such as, for example, US 3,453,257 or US 5,241,059); alkylmercury salts of thiosalicylic acid, such as thimerosal, phenylmercuric nitrate, phenylmercuric acetate, or phenylmercuric borate; parabens, such as methylparaben or propylparaben; alcohols, such as chlorobutanol, benzyl alcohol, or phenylethanol; biguanide derivatives, such as chlorhexidine or polyhexamethylene biguanide; sodium perborate; imidazolidinyl urea; sorbic acid; stable oxychloride complexes; polyethylene glycol-polyamine condensation resins; stable hydrogen peroxide generated from a hydrogen peroxide source to provide an effective trace amount of the resulting hydrogen peroxide, such as sodium perborate tetrahydrate; and / or any suitable combination thereof.

[0122] Preferred preservatives are quaternary ammonium compounds, specifically benzalkonium chloride, cetrimonium bromide and phenethyl alcohol. Where appropriate, sufficient preservatives are added to the pharmaceutical composition to ensure that secondary contamination during use is prevented.

[0123] Suitable surfactants or emulsifiers include, but are not limited to, nonionic surfactants, anionic surfactants, cationic surfactants, amphoteric surfactants, and zwitterionic surfactants.

[0124] Suitable cationic surfactants include, for example, quaternary ammonium salts. Suitable anionic surfactants include carboxylates, such as sodium or potassium salts of fatty acids; and sulfates of fatty acid salts, such as sodium laureth sulfate and sodium dodecyl sulfate.

[0125] Suitable nonionic surfactants include, but are not limited to, fatty alcohol ethers, polyol esters, polyoxyethylene esters, poloxamers, etc. Suitable polyoxyethylene esters include, but are not limited to, polyethylene glycol (PEG). Suitable polyol esters include, but are not limited to, ethylene glycol and glycerides, and sorbitan derivatives.

[0126] It should be understood that the pharmaceutical composition of the present invention for topical application should not contain ingredients that may cause irritation to the skin, even when used for a long time. Compounds that may cause allergies should be avoided. Therefore, balanced amphoteric surfactants may be preferred as surfactants.

[0127] The term "amphoteric surfactant" is well known to those skilled in the art. Such surfactants (also referred to as amphoteric surfactants) have at least one anionic group and at least one cationic group and can therefore have anionic, nonionic or cationic properties depending on the pH value. A molecule is said to be balanced if its isoelectric point occurs at pH 7. Amphoteric surfactants can have detergent and disinfectant properties. Balanced amphoteric surfactants can be particularly non-irritating to the skin and are therefore preferably used in the topical pharmaceutical compositions of the present invention.

[0128] Suitable amphoteric surfactants include aminocarboxylic acids, aminopropionic acid derivatives, imidazoline derivatives, dodecin, pendecinium or long chain betaines, or cocamidopropyl betaine.

[0129] Suitable complexing agents include, but are not limited to, those selected from the group consisting of: disodium ethylenediaminetetraacetic acid, ethylenediaminetetraacetic acid (EDTA); chelating agents having phosphonic acid or phosphonate groups, preferably organic phosphonates, specifically aminotri(lower alkylenephosphonic acids) and the like; cyclodextrins, such as α-, β- or γ-cyclodextrins, such as alkylated, hydroxyalkylated, carboxyalkylated or alkoxycarbonylalkylated derivatives, or monosaccharide- or disaccharide-α-, β- or γ-cyclodextrins, monomaltosyl- or dimaltosyl-α-, β- or γ-cyclodextrins or panosyl-cyclodextrins, and any suitable mixtures thereof.

[0130] The pharmaceutical composition of the present invention may also contain an antioxidant, such as ascorbic acid, acetylcysteine, cysteine, sodium bisulfite, butylated hydroxyanisole, butylated hydroxytoluene, or a natural or synthetic vitamin E derivative, such as alpha-tocopherol or alpha-tocopherol acetate.

[0131] In another embodiment, the pharmaceutical composition comprising compound (A) described herein may further comprise a second agent (second active ingredient, second active agent) having the desired therapeutic or preventive activity in addition to the antifungal compound (A). Such second active agents may include, but are not limited to, additional antifungal agents, antibiotics, antibodies, antiviral agents, anticancer agents, analgesics (e.g., nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, opioids, COX-2 inhibitors), immunostimulants (e.g., cytokines), hormones (natural or synthetic), central nervous system (CNS) stimulants, antiemetics, antihistamines, erythropoietin, complement stimulants, sedatives, muscle relaxants, anesthetics, anticonvulsants, antidepressants, antipsychotics, and combinations thereof.

[0132] According to a seventh aspect of the present invention, there is provided a compound (A) for use in treating a fungal condition in a human or mammal. Compound (A) may be in a pharmaceutical composition as described above for the sixth aspect of the present invention. The fungal condition in a human or mammal may be as described above. DETAILED DESCRIPTION OF THE INVENTION

[0134] In order that the present invention may be more clearly understood, embodiments thereof will now be described, by way of example only, with reference to the accompanying drawings, in which:

[0135] Figure 1 Table (Table 1) showing the relative efficacy of C12-G+, C18-TMA+ and C18-DMS+ in terms of antifungal activity and toxicity against two plant fungal infections (Septoria tritici on wheat and Magnaporthe oryzae on rice);

[0136] Figure 2 Included are 4 graphs showing the inhibitory effects of SACC C18-TMA+ and C18-DMS+ on mitochondrial potential in two plant pathogenic fungi and two human pathogenic fungi.

[0137] Figure 3 Included are 3 figures summarizing the results of LIVE / DEAD staining experiments used to assess mortality of C18-TMA+ and C18-DMS+ in a plant pathogenic fungus that causes wheat leaf blight and in two Candida species that cause infectious diseases in humans.

[0138] Figure 4 Graph showing the additional mode of action (mitochondrial reactive oxygen species production) of C18-DMS+ in three plant pathogenic fungi causing rice blast (Pyricularia oryzae), Septoria leaf blight in wheat (Septoria tritici), and corn smut (Ustilago maydis), and in two Candida species causing infectious diseases in humans;

[0139] Figure 5 Figure 2 is a graph showing an additional mode of action of C18-DMS+ (induction of programmed cell death, as shown by two staining methods in Septoria tritici);

[0140] Figure 6 To illustrate the increased potential of C18-DMS+ to protect crops from Septoria tritici and rice blast;

[0141] Figure 7 A diagram showing the additional mode of action of C18-DMS+ (induction of plant defense system);

[0142] Figure 8 For use Figure 1A table of data comparing the relative efficacy and toxicity of C12-G+ and C18-DMS+ (Table 2); and

[0143] Fig. 9 Model showing the effect of SACC on fungal oxidative phosphorylation.

[0144] Determining the effects of dodecylguanidine (dodecylguanidine) on fungal plasma membrane integrity

[0145] The physiological effects and mode of action (MoA) of a known antifungal compound, dodolin (hereafter referred to as "C12-G+"), were investigated against the basidiomycete corn smut fungus Ustilago maydis and the ascomycete wheat Septoria tritici leaf blight fungus Septoria tritici. Both fungi are economically important crop pathogens for which cell biology techniques and tools have recently been developed, including fluorescent markers for live cell imaging of all organelles.

[0146] On agar plates supplemented with C12-G+, fungal growth was inhibited in a concentration-dependent manner, with Septoria tritici being more effective against C 12 -G+ is about 4 times more sensitive than Ustilago maydis (50% growth inhibition concentration: EC 50 , Septoria tritici: 0.6 μg / ml; EC 50 , Ustilago maydis: 2.3 μg / ml. Next, the toxicity of C12-G+ was tested in liquid cultures of cells expressing the fluorescent plasma membrane marker GFP-Sso1 using live / dead cell staining. In these assays, live cells are green but turn from yellow to red when dead. Again, C12-G+ was more effective in Septoria tritici than in Ustilago maydis and killed >80% of all cells after 1 hour at 100 μg / ml (compared to approximately 15% of cells killed by Ustilago maydis under the same conditions). After incubation with C12-G+ at concentrations as high as 50 μg / ml (Ustilago maydis) or 100 μg / ml (Septoria tritici) for 30-45 minutes, the majority of cells were still alive, suggesting that studying cells under these conditions will enable understanding of the primary cellular response to the drug.

[0147] C12-G+ is believed to act on the fungal plasma membrane. Exposed cells expressing the fluorescent marker GFP-Sso1 were monitored to determine changes in the appearance of the plasma membrane. High concentrations of C12-G+ induced the formation of GFP-Sso1 "plaques" at the cell periphery of both fungi, but Septoria tritici was about 2-fold less sensitive to C12-G+ (at 50 μg / ml). Electron microscopy studies showed that cells treated with C12-G+ formed plasma membrane invaginations. These structures were recognized by antibodies against GFP, indicating that they represent GFP-Sso1 plaques. It is believed that the plasma membrane invaginations may be the result of excessive insertion of C12-G+ into the fungal plasma membrane, so the lateral diffusion of GFP-Sso1 in cells treated with C12-G+ was monitored. The reporter was photobleached in the plasma membrane, and the recovery of fluorescence was monitored, which indicated the lateral movement of the unbleached GFP-Sso1. Addition of ≥10 μg / ml C12-G+ significantly reduced the movement of GFP-Sso1 in Ustilago maydis, whereas this effect was not observed in C12-G+-treated Septoria tritici cells, indicating that SACC differentially affects the plasma membrane of the two fungi.

[0148] Drug-induced ion leakage from the cells was then determined by visualizing changes in membrane potential in C12-G+ treated cells using the voltage-sensitive fluorescent probe bis-(1,3-dibutylbarbituric acid) trimethyloxonol, DiBAC4 (3), which stains only depolarized cells. High concentrations of C12-G+ increased the number of depolarized cells in Ustilago maydis but had little effect in Septoria tritici. This result confirms that C12-G+ has a stronger effect on the plasma membrane in Ustilago maydis than in Septoria tritici. However, the low effect of C12-G+ on the plasma membrane of Septoria tritici is inconsistent with its toxicity in this fungus (see above). Therefore, effects on the plasma membrane are most likely not the primary MoA of C12-G+ in fungi.

[0149] Determining the effects of C12-G+ on fungal mitochondrial organization and respiration

[0150] The lipophilic cation C12-G+ was tested to determine if it targets the negatively charged fungal mitochondria. The accumulation of lipophilic cations in the inner membrane induces changes in the mitochondrial ultrastructure. The effect of C12-G+ was tested using a fungal strain containing a mitochondrial fluorescent marker (fluorescent reporter protein). Low concentrations of C12-G+ severely affected the shape of the mitochondria and induced fragmentation of the organelle. Electron microscopy showed that the organization of the mitochondrial inner membrane was altered, with disorganized and swollen cristae. This result supports the idea that C12-G+ is targeted to the mitochondria and inserted into the inner membrane. This membrane contains protein complexes of the respiratory chain that are able to generate the membrane potential required for the synthesis of ATP. It was also determined whether C12-G+ interferes with this oxidative phosphorylation by staining the C12-G+ treated cells with the mitochondrial potential dye tetramethylrhodamine methyl ester (TMRM), and it was found that even small amounts of C12-G+ depolarized the mitochondria in Ustilago maydis. Measurement of cellular oxygen consumption in cell suspensions confirmed that C12-G+ inhibits cellular respiration. Similar effects on membrane potential were observed in Septoria tritici, and Septoria tritici was about 4 times more sensitive to C12-G+ treatment than Ustilago maydis. This corresponds well to the approximately 4-fold increased mortality of Septoria tritici in the presence of C12-G+ (see above). Therefore, the inhibitory effect on ATP production may be the main MoA of C12-G+ in fungi.

[0151] Effects on mitochondria could explain the fungal specificity of C12-G+. To test this, mammalian skin C109 fibroblasts were treated with C12-G+ and its effects on mitochondrial shape and membrane potential were monitored.

[0152] C12-G+ had little effect on mitochondrial organization at concentrations up to 20 μg / ml, but concentrations above this resulted in organelle fragmentation and cristae swelling. This suggests that C12-G+ inserts into the inner membrane of human mitochondria, but at concentrations about 5 times higher than those in Septoria tritici (e.g. Figure 1 We also found that C12-G+ had little effect on mitochondrial membrane potential, and human cells are about 50 times less sensitive to lipid cations (e.g. Figure 1 1; compare the EC50 values ​​for depolarization in Table 1). Therefore, the inhibitory effect on mitochondrial respiration most likely supports the specificity of C12-G+ for fungi.

[0153] Determining the effect of longer alkyl chains on antifungal activity

[0154] After establishing an assay to quantitatively monitor the effects of C12-G+ on mitochondria, the synthesis and characterization of novel single alkyl chain cations (hereinafter referred to as "SACC") were performed. It has been reported that the cationic head group and the length of the alkyl chain determine the activity of SACC. Therefore, SACC combining different cationic (and one anionic) moieties containing a sulfonium head group with alkyl chains of varying lengths were synthesized and tested for their effects on Septoria tritici mitochondria. As an indicator of insertion into the mitochondrial membrane, the degree of fragmentation was monitored and the depolarization of the mitochondria was measured using TMRM staining.

[0155] The following compounds were synthesized:

[0156] (i) C12 alkyl cations with different moieties:

[0157] (dodecyltriphenylphosphonium-hereinafter referred to as "C12-TPP+";

[0158] Dodecyltrimethylammonium - hereinafter referred to as "C12-TMA+";

[0159] Dodecyltriethylammonium = C12-TEA+;

[0160] Dodecyl dimethyl sulfonium - hereinafter referred to as "C12-DMS+"),

[0161] (ii) Lipophilic cations with short C6 alkyl chains:

[0162] (Hexyltrimethylammonium-hereinafter referred to as "C6-TMA",

[0163] Hexyl dimethyl sulfonium - hereinafter referred to as "C6-DMS+") and

[0164] (iii) Lipophilic cations with longer C18 alkyl chains:

[0165] (octadecyltrimethylammonium-hereinafter referred to as "C18-TMA+",

[0166] Octadecyl dimethyl sulfonium - hereinafter referred to as "C18-DMS+",

[0167] (iv) Lipophilic alkyl anions:

[0168] Dodecyl phosphate - hereinafter referred to as "C12-PO4-")

[0169] (v) a symmetrical lipophilic cation having a dimethylsulfonium moiety at each end of the C12 alkyl chain:

[0170] (Dodecane-1,12-diylbis(dimethylsulfonium-hereinafter referred to as "++(DMS)2-C12")

[0171] At low concentrations (2.5 μg / ml), only molecules in groups (i) and (iii) induced significant mitochondrial fragmentation.

[0172] The EC50 of each compound in group (i) and group (iii) against Septoria tritici was tested and the following results were obtained:

[0173] EC50[C12-G+]: 6.63μg / ml; EC50[C12-TPP+]: 6.63μg / ml; EC50[C12-TMA+]: 3.85μg / ml; EC50[C12-TEA+] :2.38μg / ml; EC50[C12-DMS+]: 7.39μg / ml; EC50[C18-TMA+]: 1.55μg / ml; EC50[C18-DMS+]: 1.72μg / ml).

[0174] The results showed that only cationic amphiphilic molecules with long alkyl chains inserted into the mitochondrial membrane. However, when mitochondrial depolarization was tested, only C12-TPP+ and two C18 alkyl chain cations (C18-TMA+, C18-DMS+) showed significant inhibition of mitochondrial respiration in Septoria tritici. All three SACCs were tested for their ability to depolarize mitochondria in the plant pathogenic fungi Septoria tritici (which causes Septoria tritici leaf blight) and Magnaporthe oryzae (which causes rice blast). In addition, C18-TMA+, C18-DMS+ were tested for similar effects on mitochondrial potential in Candida albicans and Candida glabrata (both of which cause various infectious candidiasis). All compounds reduce the mitochondrial potential (which is required for the synthesis of ATP, the main function of mitochondria) Figure 2 ). This supports the conclusion that inhibition of respiration is the primary physiological effect of SACC. Consistent with interference with this fundamental cellular pathway, C18-TMA+ and C18-DMS+ effectively killed Septoria tritici (12-14 h exposure, 10 μg / ml) and two Candida species ( Figure 3 ; Results from LIVE / DEAD staining experiments), among which C18-DMS+ was the most toxic to Candida albicans (5 hours exposure, 100 μg / ml). The toxicity of C18-TMA+ and C18-DMS+ to Septoria tritici was 2-7 times that of C12-G+.

[0175] As a result of these experiments, only certain C12 and C18 SACC were used for subsequent testing, as it became apparent that C6 SACC and some C12 SACC were not suitable as effective antifungal agents.

[0176] Determining the toxicity of C18-TMA+ and C18-DMS+ in human cells and Daphnia magna

[0177] Low toxicity to humans and the environment is an important requirement for fungicides. Therefore, the toxicity of C12-TPP+, C18-TMA+, and C18-DMS+ was tested on C109 human skin fibroblasts. Mitochondrial organization and mitochondrial membrane potential were monitored after incubation with various concentrations of the compounds. These experiments showed that C12-TPP+ had little effect on human mitochondrial organization (EC[C12-TPP+]: 5.62μg / ml), but affected human mitochondrial respiration at low concentrations (EC50C12-TPP+: 0.355μg / ml), so it is considered too toxic to be an effective antifungal agent for most applications.

[0178] In contrast, C18-alkyl chain cations C18-TMA+ and C18-DMS+ induced mitochondrial morphological changes in fungi at 1.5-1.8 μg / ml, whereas human mitochondria were approximately 29-fold less sensitive to both SACCs than C12-G+ (e.g. Figure 1 In addition, the two compounds inhibited Septoria tritici at much lower concentrations than in human cells, indicating that the two SACCs were about 75-fold (C18-TMA+) and about 53-fold (C18-DMS+) more specific for fungi than for humans (see Table 1). Figure 1 Similar inhibition of mitochondrial respiration was found in the human pathogens Candida albicans and Candida glabrata ( Figure 2 ).

[0179] In addition, the toxicity of C12-G+, C18-TMA+, and C18-DMS+ to Daphnia magna was investigated. This freshwater crustacean is well established as a reporter organism in toxicity tests. First, Daphnia magna was treated with 1 μg / ml C12-G+, C18-TMA+, and C18-DMS+ for 30 minutes, and then the mitochondrial potential was observed by TMRM. This treatment did not affect the movement of the crustaceans. Daphnia incubated with solvent controls (without SACC) showed red fluorescence, indicating that their mitochondria were healthy. Organisms treated with C12-G+ lost most of the signal, indicating that even small amounts of C12-G+ rapidly affect mitochondrial respiration in Daphnia magna. In contrast, the two C18 alkyl chain cations had little effect on mitochondrial potential.

[0180] Next, the Daphnia were treated with varying concentrations of all three SACCs for 24 hours, and their movement behavior and "escape response" were monitored as indicators of mortality. In these experiments, C12-G+ killed all Daphnia magna at about 1 μg / ml, while C18-TMA+ and C18-DMS+ had little effect at this concentration. Higher amounts of both C18 SACCs ultimately killed Daphnia magna, with C18-TMA+ being 1.8 times more toxic than C18-DMS+. However, both C18 alkyl cations were about 5-8 times less toxic than C12-G+ (e.g. Figure 1 1).

[0181] In conclusion, the toxicity experiments showed that C18-TMA+ and C18-DMS+ were less toxic to human cultured cells and freshwater zooplankton, especially compared with C12-G+ and C12-TPP+.

[0182] Determine whether C18SACC inhibits the mitochondrial respiratory chain in multiple ways

[0183] The results of the above experiments indicate that C12-G+, C18-TMA+, and C18-DMS+ depolarize the inner mitochondrial membrane of plant and human pathogenic fungi. In mammalian cells, the lipophilic cation C12-TPP+ exerts this effect by acting as a protonophore. We set out to test whether C12-G+, C18-TMA+, and C18-DMS+ have a similar mechanism of action in Septoria tritici. Protonophores increase the formation of mitochondrial reactive oxygen species (mROS), which can be detected in living cells using the fluorescent dye dihydrorhodamine-123 (DHR-123). Treatment of Septoria tritici cells with the protonophore carbonyl cyanide m-chlorophenylhydrazone (CCCP) for 30 minutes confirmed an increase in the levels of mitochondrial reactive oxygen species (hereafter referred to as mROS). The levels of mROS were then measured in cells treated with C12-G+ and C18-TMA+. Compared with CCCP, these two compounds reduced mROS concentrations, indicating that their effects are different from CCCP ( Figure 4 , Septoria tritici). Therefore, the protonophore activity may be unique among C12-TPP+.

[0184] C12-G+ and C18-TMA+ significantly reduced mROS in Septoria tritici. Figure 4 A similar reduction in mROS was found in the human pathogenic fungus Candida glabrata treated with C18-TMA+ ( Figure 4). The main site of mROS formation in mitochondria is respiratory complex I and, to a lesser extent, respiratory complex III. Specific complex I inhibitors rotenone and antimycin A are used to block the activity of complexes I and III, respectively. Blocking complex I reduces mROS levels and is 3-4 times more effective than C12-G+ and C18-TMA+. Therefore, both SACCs inhibit complex I, but not as closely as rotenone. The inhibitor antimycin A blocks the binding of reduced coenzyme Q at complex III, thereby increasing mROS in mammalian cells. mROS increased in wheat shell spores treated with antimycin A. This was significantly reduced in the presence of C12-G+ and C18-TMA+. Therefore, in wheat shell spores, both SACCs appear to reduce electron delivery via coenzyme Q. This supports the view that SACC can interfere with the early steps of electron transfer in the inner membrane of mitochondria.

[0185] Determine whether C18-DMS+ induces mROS production and programmed fungal cell death

[0186] mROS production in C18-DMS+ treated cells was also determined in the plant pathogenic fungi Septoria tritici, Ustilago maydis, and Magnaporthe grisea, as well as the human pathogens Candida albicans and Candida glabrata. Surprisingly, the effect of C18-DMS+ was different from that of C12-G+ and C18-TMA+, as this compound significantly induced mROS levels in all fungi tested, such as Figure 4 As shown. In wheat spores, this effect mimicked CCCP, and incubation with CCCP for 24 hours reduced mROS, while treatment with C18-DMS+ for 24 hours further induced mROS production. When wheat spores cells were incubated with the complex I inhibitor rotenone, C18-DMS+ did not increase mROS levels. Therefore, C18-DMS+ may induce mROS production at respiratory complex I. Next, the importance of alkyl chain length in the ability of C18-DMS+ to trigger mROS formation was investigated. To this end, a C16 alkyl chain dimethylsulfonium cation (C16-DMS+) was also synthesized. Both this compound and C12-DMS+ (see above) were tested for their ability to induce mROS production in wheat spores. Incubation with both SACCs for 30 minutes did not increase mROS levels, either at 5μg / ml or 20μg / ml. Therefore, it seems that alkyl chain lengths greater than C16 are required for alkyl-DMS+ compounds to induce mROS.

[0187] There is increasing evidence that fungi can undergo programmed cell death, and mROS is thought to be able to induce this pathway. Therefore, programmed cell death in Septoria tritici treated with C12-G+, C18-TMA+, and C18-DMS+ was tested. TM FITC-VAD-FMK, which allows the detection of apoptosis in fungi. Co-staining with propidium iodide, a reporter of plasma membrane integrity, was performed to distinguish early apoptotic cells from dead post-apoptotic cells. After 24 hours of treatment with C18-DMS+, a significant increase in early apoptotic cells was found (CaspACE TM FITC-VAD-FMK is positive, but propidium iodide is negative; Figure 5 Only a few apoptotic cells were found after incubation with C12-G+ or C18-TMA+. This result was confirmed using annexin-V-fluorescein staining of phosphatidylserine exposed at the plasma membrane in early apoptotic cells. In addition, membrane-associated fluorescence in apoptotic cells was only found in cells treated with C18-DMS+, as shown in Figure 2. Figure 5 Thus, C18-DMS+-induced mROS production leads to activation of programmed cell death pathways in Septoria tritici and most likely also in other plant and human pathogens.

[0188] Determine the protective effects of C18-DMS+ and C18-TMA+ on plants against infection with Septoria tritici and rice blast.

[0189] As mentioned above, C12-G+, C18-TMA+ and C18-DMS+ depolarize the mitochondrial membrane and inhibit ATP synthesis, thus cutting off the pathogen’s “energy supply”. In addition, C18-DMS+ induces mROS production, which leads to mitochondrial oxidative damage and triggers programmed cell death. How this multiple mode of action enhances defense against plant pathogens in a leaf infection assay was investigated. Wheat plants whose leaves were pre-treated with all the SACCs were spray-inoculated with Septoria tritici IPO323. In addition, the ability of C12-G+, C18-TMA+ and C18-DMS+ to protect rice leaves from the rice blast fungus, Magnaporthe oryzae, was tested. It was found that all the SACCs tested inhibited the germination of the blast fungus and disrupted its appressorium formation – developmental steps that are very critical for subsequent rice infection. Conidia treated with the solvent control germinated and formed appressorium within 3 hours on the slide. In fact, all three SACCs inhibited this, with C18-TMA+ being slightly more effective than C18-DMS+. This is accompanied by mitochondrial fragmentation, changes in inner membrane organization and mitochondrial depolarization. The mROS level was also determined in the presence of all SACCs, and it was found that only C18-DMS+ induced mROS production. These results confirm the findings in wheat septoria and show that C18-DMS+ may have a greater potential for defense against rice blast. As a further preparation for plant infection experiments, wheat and rice leaves were studied to be sensitive to C12-G+, C18-TMA+ or C18-DMS+. The whole plant was sprayed with water containing a small amount of methanol solvent (= negative control), 10% Tween 20 (= positive control) and 1000 μg / ml C12-G+, C18-TMA+ and C18-DMS+ in solvent / water respectively to "leaf water dripping". Despite the use of these high concentrations, after 7 days, no SACC induced chlorosis or necrosis of wheat or rice leaves. This indicates that neither C12-G+, C18-TMA+, or C18-DMS+ are phytotoxic.

[0190] Next, quantitative wheat and rice leaf infection assays were performed. Different concentrations of all 3 SACCs were sprayed onto wheat and rice, the plants were left for 24 hours, then Septoria tritici (strain IPO323) and rice blast (strain Guy11) were applied and the appearance of disease lesions / symptoms was quantified. In the control experiment, Septoria tritici formed black spots on the chlorotic leaves after 21 days, which represented melanized conidiophores, a symptom of Septoria tritici leaf blight. Infection with rice blast resulted in the formation of brown lesions after 4 days of incubation. Symptom development was inhibited when leaves of both crops were treated with C12-G+, C18-TMA+ or C18-DMS+. This protective effect was concentration-dependent. Even at high concentrations, C12-G+ could not completely inhibit infection with Septoria tritici or rice blast, and C18-TMA+ could not completely protect against Septoria tritici leaf blight and rice blast, as Figure 6 In contrast, C18-DMS+ almost abolished symptom development in wheat and rice at 75 μg / ml and 100 μg / ml, making it particularly useful as an antifungal agent for crop protection. In fact, direct comparison of disease symptom development at high concentrations showed that C18-DMS+ provided significantly stronger protection against Septoria tritici and Magnaporthe oryzae (see Table 1). Figure 1 Table 1 and Figure 6 2).

[0191] The observed increase in plant protection with C18-DMS+ could be due to the multiple MoAs in the fungal pathogen. However, it is also possible that C18-DMS+ induces innate defenses in the plant, alerting the plant to potential pathogen attack. This priming results in an oxidative burst, including the production of hydrogen peroxide, which protects the plant from pathogen invasion. The three SACCs were tested to determine if they induce this early plant defense response by treating rice leaves with 150 μg / ml C12-G+, C18-TMA+, and C18-DMS+, followed by staining with diaminobenzidine (DAB). This dye reacts with local H2O2 to produce a reddish-brown precipitate, indicating the presence of a plant defense response. Leaves treated with the solvent showed little DAB precipitation, while treatment with 15 mM salicylic acid resulted in a brown color. C12-G+ and C18-TMA+ treatments induced slight peroxide production after 6 hours, but a much stronger DAB response was found when leaves were sprayed with C18-DMS+ (e.g., 14.3 μg / ml). Figure 7 and Figure 1 This indicates that C18-DMS+ triggers plant defense against pathogen attack, thereby enhancing the protective activity of this SACC.

[0192] Uses and advantages of the present invention

[0193] We need new fungicides to protect our thermal crops from fungal diseases, thereby ensuring food security and protecting the health of humans, animals and ecosystems. Therefore, the challenge is to discover antifungals that combine low human toxicity with low environmental impact. In addition, such chemicals must be resilient, i.e., have a multi-site mode of action and not be ineffective due to the emergence of resistance. Mitochondria are important targets for fungicide development because these organelles provide cellular ATP but also control lipid homeostasis and programmed fungal cell death. A group of novel SACCs with alkyl chain lengths greater than 16 have been synthesized and used as antifungal agents. In particular, two SACCs, namely C18-TMA+ and C18-DMS+, combine high antifungal activity with relatively low toxicity against humans, Daphnia magna and plants. C18-DMS+ in particular exhibits low toxicity and acts against fungal pathogens through multiple pathways, namely: (i) inhibition of oxidative phosphorylation, (ii) induction of destruction of mROS, (iii) triggering fungal cell apoptosis and (iv) initiation of plant defenses.

[0194] Single alkyl chain cations target fungal mitochondria

[0195] Lipophilic cations have long been known for their antimicrobial toxicity and have recently been recognized as antifungal compounds for medical use. One of these biocidal cations is SACC, which combines a cationic head group with a long n-alkyl chain. This simple amphiphilic organization suggests that SACC is able to insert into the membrane. In fact, many studies report that SACC such as CTAB (hexadecyltrimethylammonium bromide) or C12-G+ (dodecylguanidine, also known as dodecyl) can change the permeability or function of the plasma membrane. Before SACC reaches the plasma membrane, they must pass through the fungal cell wall. In the process, they can change the surface charge of the fungal cell, which is described as the main effect supporting the fungal toxicity of these compounds. Therefore, antifungal lipid cations, including SACC, are believed to act on the surface of fungal cells, which is reflected in the name "cationic surfactant".

[0196] However, many results contradict this assumed MoA in fungi. Early reports on the mode of action of dodolin indicated that at high concentrations, this fungicide permeated the plasma membrane, but the fungal cells were dead. Other reports have shown that dodolin is able to inhibit important metabolic enzymes, indicating that lipophilic cations cross the plasma membrane and exert their primary fungal toxic effects within the fungal cell. Once beyond the plasma membrane, the positively charged SACCs may accumulate in the negatively charged mitochondrial matrix, where they insert into the mitochondrial inner membrane. The results detailed in this article support this concept. Although high concentrations of C12-G+ affect the fungal plasma membrane (EC50 of about 20-50 μg / ml in Septoria tritici), all SACCs tested induced mitochondrial fragmentation and altered the appearance of the mitochondrial inner membrane (EC50 in Septoria tritici <7 μg / ml). In addition, all seven long-chain SACCs tested showed more potent inhibition of mitochondrial respiration (EC50 in Septoria tritici <2 μg / ml), and these results were confirmed in Ustilago maydis and Magnaporthe oryzae using selected SACCs. Therefore, it is believed that SACC targets mitochondria and interferes with oxidative phosphorylation in fungi.

[0197] Multiple effects of monoalkyl chain cations on mitochondrial respiration

[0198] Electron transport through the mitochondrial respiratory chain complexes pumps protons into the mitochondrial inner space, making the matrix negatively charged. This spatial charge separation generates the proton motive force for the synthesis of ATP. SACC depolarizes the inner membrane, thereby disrupting ATP production, effectively “cutting off” the energy supply to the fungal cell. Previous studies using isolated mitochondria have shown that C12-TPP+ depolarizes mitochondria by interacting with negatively charged fatty acid residues, which results in a mild uncoupling effect. Therefore, the tested SACCs might promote the uncontrolled entry of protons into the mitochondrial matrix. However, monitoring mROS production in S. tritici revealed that SACCs act differently from the protonophore CCCP. Furthermore, the uncoupling activity of C12TPP+ requires a delocalized cationic charge, whereas SACC carries a localized charge. Therefore, C12-TPP+ might have unique effects on the fungal mitochondrial respiratory chain, which could explain its high toxicity. However, the results cannot exclude a mild uncoupling effect of the tested SACCs.

[0199] Without being bound by any theory, it is believed that lipophilic cations can inhibit respiratory complex I and / or complex III in isolated mitochondria. In fungi, complex I is supplemented by fungus-specific alternative dehydrogenases. Both are capable of reducing coenzyme Q, which delivers electrons to complex III. As a byproduct, both complex I and III produce low levels of mROS. C12-G+ and C18-TMA+ reduced the basal level of mROS in Septoria tritici and also reduced antimycin A-induced mROS formation in complex III. Therefore, SACC may interfere with the early steps of the electron transport chain. One possibility is that membrane-inserted SACC changes the surface charge of these membrane-bound enzymes, thereby interfering with their activity. In addition, SACC can change the fluidity of the membrane, thereby interfering with the assembly and function of complex I, as this requires it to diffuse through the inner membrane and has been shown to be dependent on the lipid composition of the inner membrane. In addition, lipophilic cations can directly bind to proteins of the respiratory complexes. Indeed, the specific complex I inhibitor 2-decyl-4-quinazolinamine (DQA) binds directly to purified complex I and is predicted to be a lipophilic cation at physiological pH. Therefore, interference with early steps in the respiratory chain via inhibition of fungal alternative NADH dehydrogenases and / or fungal-specific proteins in complex I could explain the specificity of SACC for fungal cells.

[0200] C18-DMS+ and C18-TMA+ fight fungal pathogens through multiple modes of action.

[0201] As shown, the most effective antifungal SACC against Septoria tritici was C18-DMS+. This compound was more fungitoxic and more effective in inhibiting respiration (e.g., Figure 8 Importantly, the enhanced antifungal properties of C18-DMS+ were accompanied by lower toxicity to human cells and Daphnia magna. Although C18-DMS+ was less effective in inhibiting oxidative phosphorylation than the quaternary ammonium cation C18-TMA+ (e.g. Figure 11), but was significantly more effective in protecting wheat and rice against fungal pathogens than other C12-G+ and C12-TPP+. This improved protective performance may be due to the fact that C18-DMS+ and C18-TMA+ "attack" fungal pathogens in multiple ways. C18-DMS+ in particular appears to inhibit and kill fungi through multiple actions, namely: (i) like other SACCs, the compound inhibits oxidative phosphorylation, thereby depriving fungal cells of ATP; (ii) it induces the production of mROS, most likely involving complex I, which leads to oxidative damage to mitochondrial lipids and proteins; (iii) C18-DMS+ dispatches pathogens along an irreversible programmed cell death pathway; (iv) finally, C18-DMS+ triggers the formation of hydrogen peroxide in plants, indicating an oxidative burst that triggers early plant defense responses. Therefore, C18-DMS+ triggers plant defense against pathogen attack, thereby reducing the chances of successful fungal infection.

[0202] C18-TMA+ and C18-DMS+ differ only in their head groups, suggesting that the additional physiological effects in fungal cells are due to the dimethylsulfonium moiety. Key to the physiological effects of C18-DMS+ in fungi is its ability to induce mROS production. This has been seen in Septoria tritici, Magnaporthe oryzae, and Ustilago maydis, and is therefore a general feature of C18-DMS+. Interestingly, when attached to C12 or C16 alkyl chains, the dimethylsulfonium moiety did not induce mROS, even at high concentrations. This result suggests that the length of the alkyl chain is crucial for the function of the cationic head group. This finding was surprising, as even slightly shorter hydrophobic C16 alkyl chains do not integrate efficiently into the mitochondrial inner membrane, and only chain lengths longer than C16 showed mROS induction.

[0203] in conclusion

[0204] Surprisingly, C18-DMS+ and C18-TMA+ are more effective antifungals than any C6 or C12 alkyl chain length compounds tested. C18-DMS+ and C18-TMA+ are more effective than other tested SACCs for corn smut fungus Ustilago maydis, wheat septoria leaf blight pathogen wheat septoria and rice blast fungus Pyricularia oryzae in general (with respect to C18-DMS+, in substantially all modes of action). In general, pathogens tested crops that provide two-thirds of the calories in a human diet. Figure 1 Table 1 shows that C18-DMS+ and C18-TMA+ have higher efficacy and lower toxicity than the well-known SACC antifungal compound dodine, and Figure 8 Table 2 also shows the extent to which C18-DMS+ is more effective than dodine.

[0205] Second, both C18-DMS+ and C18-TMA+ target the fungal respiratory chain in multiple ways, with C18-DMS+ causing mROS at respiratory complex I, which is expected to damage mitochondrial proteins and lipids, but also triggers fungal cell apoptosis, e.g. Fig. 9 shown.

[0206] Finally, the C18 SACCs tested showed relatively low toxicity in human cultured cells and Daphnia magna (compared to known SACC fungicides), with C12-TPP+ showing unexpectedly high toxicity to human cultured cells; and C12-G+ did not protect plants from pathogens to an appropriate extent.

[0207] The identification of C18-DMS+ and C18-TMA+ and thus C17-C32 alkyl chain cations with dialkyl or trialkyl substituted cationic moieties as particularly effective antifungal agents, which act via a range of modes of operation and have significantly lower toxicity (human and / or environmental toxicity) compared to C12-G+, indicates that the compounds and compositions of the present invention have great potential as fungicides in crop protection.

[0208] Other Uses

[0209] Due to their low toxicity to humans and antifungal efficacy, the C17-C32 SACC compositions of the present invention can be used to treat (prevent or improve) building and construction materials, particularly wood, wall coverings (such as wallpaper), floor coverings (such as carpet or linoleum) and paints. The SACC compositions can be incorporated during the manufacturing process of building or construction materials, or can be impregnated or coated on the materials after manufacturing.

[0210] The SACC compositions of the invention may also be used in cleaning or disinfecting compositions, both against fungi and other microorganisms (e.g., oomycetes, archaea), which may be used, for example, prophylactically to prevent the growth of pathogens on surfaces or to remove infestations of surfaces.

[0211] The SACC composition of the present invention can also be used in soil or other plant growth media to remove fungi, limit the spread of fungi or control the growth of fungi. It can be applied in any suitable manner, such as by spraying or sprinkling.

[0212] The C18-DMS+, C18-TMA+ and other C17+ SACC compositions of the present invention can be incorporated into pharmaceutical compositions, particularly for topical administration to humans, non-human mammals and other animals.

[0213] The above embodiments are described by way of example only. Many changes may be made without departing from the scope of the invention as defined in the appended claims.

Claims

1. A pharmaceutical composition comprising a compound of formula R-S+(R') 2 or R-N+(R') 3 Antifungal compounds wherein R is a C17-C32 straight or branched chain alkyl; and Each R' is independently methyl, ethyl, propyl, isopropyl or butyl; and pharmaceutically acceptable carriers or excipients.

2. The pharmaceutical composition according to claim 1, wherein R is a C18 alkyl group.

3. The pharmaceutical composition according to claim 1 or 2, wherein each R' is a methyl group.

4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the antifungal compound is octadecyltrimethylammonium or octadecyldimethylsulfonium.

5. The pharmaceutical composition according to any one of the preceding claims, wherein the antifungal compound comprises a counterion selected from chloride, bromide, iodide, hydroxide, sulfate, phosphate, bisulfate or acetate.

6. A pharmaceutical composition according to any one of the preceding claims, wherein the antifungal compound is dissolved or suspended in an aqueous carrier.

7. A pharmaceutical composition according to any one of the preceding claims, wherein the pharmaceutically acceptable carrier or excipient comprises a solvent, a co-solvent, an oil or fat, a natural wax, a petroleum wax, a hydrocarbon or any suitable combination thereof.

8. A pharmaceutical composition according to any one of the preceding claims, wherein the pharmaceutically acceptable carrier or excipient comprises an organic solvent.

9. The pharmaceutical composition according to any one of the preceding claims, wherein the pharmaceutical composition is a topically administrable pharmaceutical composition.

10. The pharmaceutical composition according to any one of the preceding claims, wherein the pharmaceutical composition is an ointment, a cream or a spray.

11. The pharmaceutical composition according to any one of claims 1 to 9, wherein the pharmaceutical composition is encapsulated.

12. A pharmaceutical composition according to any one of the preceding claims comprising one or more additional antifungal agents.

13. An antifungal compound having the formula RS + (R') 2 or RN + (R') 3 wherein R is a C17-C32 straight or branched chain alkyl; and Each R' is independently methyl, ethyl, propyl, isopropyl or butyl; The antifungal compounds are useful for treating fungal conditions in humans or non-human animals.

14. The antifungal compound according to claim 13, wherein the compound is octadecyltrimethylammonium or octadecyldimethylsulfonium.

15. Type RS + (R') 2 or RN + (R') 3 Use of a compound in the preparation of an antifungal agent for treating fungal diseases in humans or non-human animals wherein R is a C17-C32 straight or branched chain alkyl; and Each R' is independently methyl, ethyl, propyl, isopropyl or butyl.

16. Type RS + (R') 2 or RN + (R') 3 Use of an antifungal compound in the preparation of a medicament for treating fungal infections in humans or non-human animals, wherein the treatment destroys, controls or inhibits the fungus by contacting the fungus with the antifungal compound in, R is a C17-C32 straight or branched chain alkyl; and Each R' is independently methyl, ethyl, propyl, isopropyl or butyl.

17. The use according to claim 16, wherein the antifungal compound is applied in the form of a composition comprising 0.1-200 μg / ml of the compound.

18. Use according to claim 16 or claim 17, wherein the antifungal compound is applied topically as a composition.

19. The use according to claim 18, wherein the composition is according to any one of claims 1-12.

20. The use according to any one of claims 15 to 19, wherein the antifungal compound is octadecyltrimethylammonium or octadecyldimethylsulfonium.